- Global Pharma News & Resources

Impact of the ATTC Network after 18 months of operation

Just 18 months ago, the Advanced Therapy Treatment Centre (ATTC) network was set up through funding from the UK Research and Innovation Industrial Strategy Challenge Fund. The network was set up in response to the challenge faced by the UK to bring cell and gene therapies into routine medical practice and anticipated dramatic increase in clinical trial activity across the country. The introduction of these novel therapies, and the challenges this brings, has created an opportunity to place the UK at the forefront of this technology and for the country to be the place to bring these treatments to patients as they move from clinical trial to marketed products.

Since its inception, the three Innovate UK funded ATTCs (iMATCH, MW-ATTC and NA-ATTC) have been working to smooth the path to adoption and develop ways of working within and across centres and supply chain that will support the increased clinical use of ATMPs. The collaboration across the industrial and NHS partners has begun to produce guidance documents and approaches to standardisation.

The success of the network is now attracting all the major companies operating in the UK as a way of solving the problems, connecting the professionals and accelerating patient access to these novel therapies.

Watch the video to see how far the ATTC Network has come in the past 18 months

The video can be accessed from

About Cell and Gene Therapy Catapult:

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 200 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit or visit


About the Advanced Therapy Treatment Centres:

The centres; Innovate Manchester Advanced Therapy Centre Hub (iMATCH), the Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC, comprising Birmingham, Wales and Nottingham) and the Northern Alliance Advanced Therapies Treatment Centre (NAATTC, comprising Scotland, Newcastle and Leeds) will develop systems and processes within the trusts and hospitals capable of delivering advanced therapies at scale to patients across the NHS. The learnings and systems from the initial centres will be rolled out to other centres in the UK. In March 2018, the centres were awarded £21 million from the Industrial Strategy Challenge Fund with further funding available to support the delivery of projects by the network.


FTI Consulting for the CGT Catapult:

Michael Trace +44 (0) 203 319 5674 / 

George Kendrick +44 (0) 203 319 5674 / 

Editor Details

  • Company:
    • Advanced Therapy Treatment Centre (ATTC)
  • Name:
    • Advanced Therapy Treatment Centre (ATTC)
Last Updated: 08-Jan-2020